UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest reported) November 26, 2002
Advanced Biotherapy, Inc.
| Delaware | 0-26323 | 95-0402415 | ||
|
|
||||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 6355 Topanga Canyon Boulevard, Suite 510 Woodland Hills, California |
91367 |
|
|
|
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (818) 883-6716
| Item 5. OTHER EVENTS. | ||||||||
| Item 7. FINANCIAL STATEMENTS AND EXHIBITS | ||||||||
| Signatures | ||||||||
| INDEX TO EXHIBITS | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 5. OTHER EVENTS.
The registrant published a press release on November 26, 2002, which reported that Advanced Biotherapy, Inc. has a patent application pending for the exclusive use of any form of antibody to gamma interferon (IFN-g) for the treatment of Pemphigus Vulgaris.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
| (c) | Exhibits. |
| Designation | Description of Exhibit | |
99.1 |
Press Release, dated November 26, 2002 |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ADVANCED BIOTHERAPY, INC. (Registrant) |
||||
| Date: November 26, 2002 | By: | /s/ Edmond Buccellato | ||
| Edmond Buccellato, President and CEO | ||||
INDEX TO EXHIBITS
| Exhibit | Description | |
| 99.1 |
Text of Press Release, dated November 26, 2002 |